Cargando…

Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts

Glioma is the most common malignant tumor of the central nervous system. Tumor purity is a source of important prognostic factor for glioma patients, showing the key roles of the microenvironment in glioma prognosis. In this study, we systematically screened functional characterization related to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chunlong, Zhang, Yuxi, Tan, Guiyuan, Mi, Wanqi, Zhong, Xiaoling, Zhang, Yu, Zhao, Ziyan, Li, Feng, Xu, Yanjun, Zhang, Yunpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168240/
https://www.ncbi.nlm.nih.gov/pubmed/35677045
http://dx.doi.org/10.3389/fimmu.2022.853074
_version_ 1784720960043089920
author Zhang, Chunlong
Zhang, Yuxi
Tan, Guiyuan
Mi, Wanqi
Zhong, Xiaoling
Zhang, Yu
Zhao, Ziyan
Li, Feng
Xu, Yanjun
Zhang, Yunpeng
author_facet Zhang, Chunlong
Zhang, Yuxi
Tan, Guiyuan
Mi, Wanqi
Zhong, Xiaoling
Zhang, Yu
Zhao, Ziyan
Li, Feng
Xu, Yanjun
Zhang, Yunpeng
author_sort Zhang, Chunlong
collection PubMed
description Glioma is the most common malignant tumor of the central nervous system. Tumor purity is a source of important prognostic factor for glioma patients, showing the key roles of the microenvironment in glioma prognosis. In this study, we systematically screened functional characterization related to the tumor immune microenvironment and constructed a risk model named Glioma MicroEnvironment Functional Signature (GMEFS) based on eight cohorts. The prognostic value of the GMEFS model was also verified in another two glioma cohorts, glioblastoma (GBM) and low-grade glioma (LGG) cohorts, from The Cancer Genome Atlas (TCGA). Nomograms were established in the training and testing cohorts to validate the clinical use of this model. Furthermore, the relationships between the risk score, intrinsic molecular subtypes, tumor purity, and tumor-infiltrating immune cell abundance were also evaluated. Meanwhile, the performance of the GMEFS model in glioma formation and glioma recurrence was systematically analyzed based on 16 glioma cohorts from the Gene Expression Omnibus (GEO) database. Based on multiple-cohort integrated analysis, risk subpathway signatures were identified, and a drug–subpathway association network was further constructed to explore candidate therapy target regions. Three subpathways derived from Focal adhesion (path: 04510) were identified and contained known targets including platelet derived growth factor receptor alpha (PDGFRA), epidermal growth factor receptor (EGFR), and erb-b2 receptor tyrosine kinase 2 (ERBB2). In conclusion, the novel functional signatures identified in this study could serve as a robust prognostic biomarker, and this study provided a framework to identify candidate therapeutic target regions, which further guide glioma patients’ clinical decision.
format Online
Article
Text
id pubmed-9168240
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91682402022-06-07 Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts Zhang, Chunlong Zhang, Yuxi Tan, Guiyuan Mi, Wanqi Zhong, Xiaoling Zhang, Yu Zhao, Ziyan Li, Feng Xu, Yanjun Zhang, Yunpeng Front Immunol Immunology Glioma is the most common malignant tumor of the central nervous system. Tumor purity is a source of important prognostic factor for glioma patients, showing the key roles of the microenvironment in glioma prognosis. In this study, we systematically screened functional characterization related to the tumor immune microenvironment and constructed a risk model named Glioma MicroEnvironment Functional Signature (GMEFS) based on eight cohorts. The prognostic value of the GMEFS model was also verified in another two glioma cohorts, glioblastoma (GBM) and low-grade glioma (LGG) cohorts, from The Cancer Genome Atlas (TCGA). Nomograms were established in the training and testing cohorts to validate the clinical use of this model. Furthermore, the relationships between the risk score, intrinsic molecular subtypes, tumor purity, and tumor-infiltrating immune cell abundance were also evaluated. Meanwhile, the performance of the GMEFS model in glioma formation and glioma recurrence was systematically analyzed based on 16 glioma cohorts from the Gene Expression Omnibus (GEO) database. Based on multiple-cohort integrated analysis, risk subpathway signatures were identified, and a drug–subpathway association network was further constructed to explore candidate therapy target regions. Three subpathways derived from Focal adhesion (path: 04510) were identified and contained known targets including platelet derived growth factor receptor alpha (PDGFRA), epidermal growth factor receptor (EGFR), and erb-b2 receptor tyrosine kinase 2 (ERBB2). In conclusion, the novel functional signatures identified in this study could serve as a robust prognostic biomarker, and this study provided a framework to identify candidate therapeutic target regions, which further guide glioma patients’ clinical decision. Frontiers Media S.A. 2022-05-23 /pmc/articles/PMC9168240/ /pubmed/35677045 http://dx.doi.org/10.3389/fimmu.2022.853074 Text en Copyright © 2022 Zhang, Zhang, Tan, Mi, Zhong, Zhang, Zhao, Li, Xu and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Chunlong
Zhang, Yuxi
Tan, Guiyuan
Mi, Wanqi
Zhong, Xiaoling
Zhang, Yu
Zhao, Ziyan
Li, Feng
Xu, Yanjun
Zhang, Yunpeng
Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts
title Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts
title_full Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts
title_fullStr Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts
title_full_unstemmed Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts
title_short Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts
title_sort prognostic features of the tumor immune microenvironment in glioma and their clinical applications: analysis of multiple cohorts
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168240/
https://www.ncbi.nlm.nih.gov/pubmed/35677045
http://dx.doi.org/10.3389/fimmu.2022.853074
work_keys_str_mv AT zhangchunlong prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts
AT zhangyuxi prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts
AT tanguiyuan prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts
AT miwanqi prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts
AT zhongxiaoling prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts
AT zhangyu prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts
AT zhaoziyan prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts
AT lifeng prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts
AT xuyanjun prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts
AT zhangyunpeng prognosticfeaturesofthetumorimmunemicroenvironmentingliomaandtheirclinicalapplicationsanalysisofmultiplecohorts